Vise Technologies Inc. Takes $646,000 Position in Chemed Corporation $CHE

Vise Technologies Inc. purchased a new stake in Chemed Corporation (NYSE:CHE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,386 shares of the company’s stock, valued at approximately $646,000.

A number of other hedge funds have also recently added to or reduced their stakes in CHE. TD Asset Management Inc raised its holdings in shares of Chemed by 7.5% during the 4th quarter. TD Asset Management Inc now owns 324,546 shares of the company’s stock valued at $138,860,000 after purchasing an additional 22,715 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Chemed by 14.5% in the 4th quarter. BNP Paribas Financial Markets now owns 35,024 shares of the company’s stock valued at $14,985,000 after purchasing an additional 4,430 shares during the last quarter. Epoch Investment Partners Inc. boosted its holdings in Chemed by 4.9% in the fourth quarter. Epoch Investment Partners Inc. now owns 322,408 shares of the company’s stock worth $137,945,000 after purchasing an additional 15,133 shares in the last quarter. Abacus FCF Advisors LLC bought a new stake in Chemed in the fourth quarter worth $5,935,000. Finally, C WorldWide Group Holding A S acquired a new position in Chemed during the fourth quarter worth $2,189,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Stock Performance

Shares of NYSE CHE opened at $541.33 on Monday. The company has a quick ratio of 0.89, a current ratio of 0.91 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $499.24 and its two-hundred day moving average is $446.50. The company has a market cap of $7.08 billion, a P/E ratio of 27.19, a P/E/G ratio of 2.05 and a beta of 0.51. Chemed Corporation has a 12 month low of $365.20 and a 12 month high of $557.00.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating the consensus estimate of $5.60 by $0.46. Chemed had a return on equity of 31.77% and a net margin of 10.60%.The company had revenue of $673.25 million during the quarter, compared to analysts’ expectations of $665.04 million. During the same period in the prior year, the business earned $4.27 earnings per share. Chemed’s revenue for the quarter was up 8.8% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, equities analysts expect that Chemed Corporation will post 23.18 EPS for the current year.

Chemed Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th will be given a $0.70 dividend. The ex-dividend date is Monday, August 17th. This represents a $2.80 annualized dividend and a yield of 0.5%. This is a positive change from Chemed’s previous quarterly dividend of $0.60. Chemed’s dividend payout ratio (DPR) is 14.06%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CHE shares. Oppenheimer raised their target price on Chemed from $500.00 to $590.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Weiss Ratings upgraded Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. Wall Street Zen raised Chemed from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Bank of America reissued a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada boosted their target price on Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $530.75.

Insider Transactions at Chemed

In other news, Director Patrick P. Grace sold 190 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $532.00, for a total transaction of $101,080.00. Following the transaction, the director owned 3,533 shares in the company, valued at approximately $1,879,556. The trade was a 5.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the transaction, the chief executive officer directly owned 70,418 shares of the company’s stock, valued at $37,991,215.18. This represents a 2.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,537 shares of company stock worth $1,782,654. 3.33% of the stock is currently owned by company insiders.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.